Interrad Medical this week announced that it formed a strategic partnership with Eloquest Healthcare to expand sales of SecurAcath in the U.S.
Through the partnership, the companies will provide hospitals and clinicians with Interred Medical’s SecurAcath to improve outcomes and reduce medical expenses, according to the company.
“We are excited to have the SecurAcath included with Eloquest’s complimentary, problem-solving products,” Interrad Medical president and CEO Joe Goldberger said in a news release. “Eloquest Healthcare is known for delivering innovative solutions that improve the standard of care with an emphasis on infection prevention and improved patient care, making them an excellent partner for Interrad Medical.”
SecurAcath is a subcutaneous catheter securement device that the company designed to reduce the risk of catheter-related infections and decrease catheter dislodgment and migration. In clinical data publications, SecurAcath showed dislodgment rates of 0-1.6%, according to the company.
“Securement-related catheter complications, including infections and dislodgements, are unacceptably high,” Eloquent Healthcare president and CEO Tim O’Halla said. “Current catheter securement methods of sutures and adhesive devices have shown to have higher complication rates than the SecurAcath. The innovative SecurAcath device is a perfect fit with our mission to improve the standard of care while reducing total cost of patient care.”
